Neptune Technologies & Bioressources
Basic Shares: 48.2 million
Fully diluted: 53.9 million
The Life Sciences Report published an interview today called “Chen Lin’s Key to Huge Biotech Profits: Make It Personal”. In the article Mr. Lin specifically talks about Neptune Technologies & Acasti Pharma as two of the life science stocks in which he has invested. He started following these two companies because his mother personally benefited from taking krill oil as it lowered her triglycerides.
Mr. Lin also talks about how he has diversified his resource heavy portfolio with “life sciences suitable for retail investors.” He draws comparisons between mining and resource stocks in that there is potential for high risk and high reward. “It depends on the stock you pick. Some resource stocks grow very, very rapidly. You can have a ten-bagger very quickly. It is the same for biotech. If you pick the right stock, it can have very high returns.”
To view the full interview, please click here - http://www.thelifesciencesreport.com/pub/na/14192
About Chen Lin
What is Chen Buying? What is Chen Selling? This is a stock newsletter published and distributed by Taylor Hard Money Advisors, Inc., Publisher of J Taylor's Gold, Energy & Tech Stocks and Roger Wiegand's Trader Tracks
Taylor Hard Money Advisors, Inc. has established a joint venture arrangement with Chen Lin, a Chinese doctoral candidate in aeronautical engineering at Princeton. Chen found his investment strategies were so profitable that he put his Ph.D. on the back burner. Even now when most folks are finding their retirement accounts declining drastically, Chen has continued to turn out exceptional profits using both a value-orientated approach as well as technical analysis for market timing.
Chen's track record is phenomenal! He invests money for his family in several different accounts, some of which are more aggressive than others. But the one account we use to track his personal investment performance is his wife Emily's Roth IRA account. We use that one because it is the easiest to document and calculate returns with no new money added since the beginning date. In December 2002 that account was worth $5,411. Despite a difficult year of 2011, this account has now grown to $2,002,327 as of June 30, 2012: